A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a ...

Large language models (LLMs) aren’t actually giant computer brains. Instead, they are effectively massive vector spaces in ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be ...

Silicon Valley’s timeline for "solving" human health is dangerously optimistic, but AI is quietly breaking pharma’s biggest ...